IO Biotech (IOBT) Stock Analysis
NASDAQHealthcareBiotechnology
What IO Biotech does
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is progressing through Phase 2 clinical trials for melanoma and is also being evaluated in Phase 1 trials across a range of other cancers, including lung, head and neck, bladder, and melanoma. Additionally, IO Biotech is developing IO112, a distinct product candidate. IO112 comprises a single Arginase 1-derived peptide designed to specifically target T cells that identify epitopes originating from Arginase 1, aiming to treat various malignancies. Established in 2014, the company is headquartered in Copenhagen, Denmark.
Key metrics
ETFs linked to IOBT
Broad-market and Healthcare sector ETFs an investor holding IO Biotech is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how IOBT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze IOBT in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for IO Biotech?
- IO Biotech trades under the ticker IOBT on NASDAQ.
- Which exchange is IOBT listed on?
- IOBT is listed on NASDAQ.
- What sector does IO Biotech operate in?
- IO Biotech is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze IOBT in a portfolio?
- PortView shows IOBT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.